HeartWare International Inc  

(Public, NASDAQ:HTWR)   Watch this stock  
Find more results for htwr
-2.43 (-2.85%)
Jul 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 82.54 - 86.66
52 week 69.05 - 95.59
Open 84.83
Vol / Avg. 0.00/252,639.00
Mkt cap 1.47B
P/E     -
Div/yield     -
EPS -0.85
Shares 17.26M
Beta 0.05
Inst. own 112%
Aug 13, 2015
HeartWare International Inc at Canaccord Genuity Growth Conference - 8:30AM EDT - Add to calendar
Jul 30, 2015
Q2 2015 HeartWare International Inc Earnings Release - 9:30AM EDT - Add to calendar
Jul 30, 2015
Q2 2015 HeartWare International Inc Earnings Call - 8:00AM EDT - Add to calendar
Jun 11, 2015
HeartWare International Inc at Goldman Sachs Healthcare Conference
Jun 4, 2015
HeartWare International Inc Annual Shareholders Meeting
May 14, 2015
HeartWare International Inc at Bank of America Merrill Lynch Health Care Conference
Apr 30, 2015
Q1 2015 HeartWare International Inc Earnings Release
Apr 30, 2015
Q1 2015 HeartWare International Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -20.76% -6.96%
Operating margin -10.45% -0.04%
EBITD margin - -5.37%
Return on average assets -13.92% -4.54%
Return on average equity -28.54% -9.51%
Employees 585 -
CDP Score - -


500 Old Connecticut Path
United States - Map
+1-508-7390873 (Phone)
+1-508-7390948 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Heartware International, Inc. is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices for patients suffering from advanced heart failure. The HeartWare Ventricular Assist System (HVAD System), which includes a ventricular assist device (VAD) or blood pump, patient accessories and surgical tools, provides circulatory support for patients in the advanced stage of heart failure. The core of the HVAD System is a continuous flow blood pump, the HVAD pump. The HVAD System is designed to be implanted adjacent to the heart, avoiding abdominal surgery, directly adjacent to the heart. The Company's hybrid system is used for suspending the impeller. The impeller is suspended within the pump housing by the opposing forces of passive magnets and hydrodynamic thrust generated by the pump impeller, which circulates a cushion of blood.

Officers and directors

C. Raymond Larkin Jr. Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Douglas Evan Godshall M.B.A. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Seth L. Harrison M.D. Deputy Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Peter F. McAree Chief Financial Officer, Senior Vice President, Treasurer
Age: 50
Bio & Compensation  - Reuters
Jeffrey A. LaRose Executive Vice President, Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Lawrence Knopf Senior Vice President, General Counsel, Secretary
Age: 53
Bio & Compensation  - Reuters
James Schuermann Senior Vice President - Sales and Marketing
Age: 46
Bio & Compensation  - Reuters
Mark Strong Senior Vice President, Research and Development and Quality Assurance
Age: 43
Bio & Compensation  - Reuters
Robert Yocher Senior Vice President, Regulatory Affairs
Age: 63
Bio & Compensation  - Reuters
Katrin Leadley M.D. Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters